hrp0089p2-p343 | Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology P2 | ESPE2018

Clinical, Biochemical, Structural and Functional Characterization of a Novel P450 Oxidoreductase Mutation Causing Virilization in a 46,XX Patient

Camats Nuria , Benito-Sanz Sara , Parween Shaheena , Lopez-Siguero Juan-Pedro , Fernandez-Cancio Monica , Fluck Christa E , Udhane Sameer S , Kagawa Norio , Audi Laura , Pandey Amit V

Background: Cytochrome P450 oxidoreductase (POR) deficiency (PORD) is a form of congenital adrenal hyperplasia (CAH) and results in steroid-production loss from cytochrome P450 proteins. Mutations in POR cause mild to severe forms of CAH with/without bone malformation symptoms resembling Antley-Bixler syndrome. We report a novel POR Arg550Trp mutation identified in a 46,XX patient with signs of aromatase (ARO) deficiency. Child (first pregnancy) and mother pr...

hrp0086rfc8.1 | Growth: Clinical | ESPE2016

Somavaratan (VRS-317) Treatment of Children with Growth Hormone Deficiency (GHD): Results at 2 Years (NCT02068521)

Bright George , Moore Wayne V. , Nguyen Huong Jil , Kletter Gad B. , Miller Bradley S. , Fechner Patricia Y. , Ng David , Humphriss Eric , Cleland Jeffrey L.

Background: Somavaratan, a novel long-acting rhGH fusion protein with t1/2>100 h, previously demonstrated clinically meaningful improvements in height velocity (HV) and IGF-I in prepubertal GHD children (Moore JCEM 2016).Objective and hypotheses: To evaluate maintenance of somavaratan treatment effects in the 2nd treatment year.Method: After subcutaneous pediatric doses were evaluated in a single dose PK/PD study (<e...

hrp0086p2-p297 | Diabetes P2 | ESPE2016

Clinical and Demographic Characteristics of Patients with Type 1 Diabetes Mellitus and correlation with risk factors: A South Indian Database

Nagesh V. Sri , Sethi Bipin , Mendu Vishnuvardhan Rao , Kelwade Jayant , Parekh Harsh , Dukle Vaibhav , Hashmi Syed Mustafa , Hyder Sana , Jiwani Sania , Waseem Ayesha

Background: Type 1 Diabetes (T1DM) is one of the most common paediatric endocrine disorders in India, but diagnosis is often delayed. Moreover, systematized data about symptoms, presentation, management and follow-up of T1DM in India is lacking. Absence of such data makes formulation of uniform region and nationwide protocols for diagnosis, management and follow-up of T1DM patients difficult.Objective and hypotheses: To generate data about presentation a...

hrp0082p1-d3-171 | Growth (2) | ESPE2014

Safety and Efficacy Results of a 6 Month, Randomized, Multi-Center Trial of a Novel Long-Acting rhGH (VRS-317) in Naïve to Treatment, Pre-Pubertal Children with GH Deficiency

Bright George M , Moore Wayne V , Nguyen H Q , Kletter Gad B , Miller Bradley S , Rogers Douglas G , Humphriss Eric , Cleland Jeffrey

Background: VRS-317, a novel fusion protein of rhGH, was safe and well tolerated in single dose studies of adults and children with growth harmone deficiency (GHD).Objectives: Conduct a 6-month study to determine the safety, tolerability, height velocity and IGF1 response in GHD children.Methods: 64 subjects were randomized into three arms to evaluate monthly, semi-monthly and weekly dosing.Results: At VRS-31...

hrp0084p2-382 | Fat | ESPE2015

Insulin-Like Factor 5 –A Novel Orexigenic Hormone in Humans is Dysregulated in Obesity

Wagner Isabel V , Flehmig Gesine , Scheuermann Kathrin , Loffler Dennis , Korner Antje , Kiess Wieland , Stumvoll Michael , Dietrich Arne , Blueher Matthias , Kloting Nora , Soder Olle , Svechnikov Konstantin

Background: Insulin-like factor 5 (INSL5), a member of the insulin superfamily, is expressed in the colorectum and hypothalamus. INSL5 levels are elevated by prolonged calorie restriction and declined with feeding, suggesting that it might be an orexigenic hormone.Objectives and hypotheses: Our aim was to explore the relationship between INSL5 and different metabolic parameters in lean and obese subjects and to identify possible links between INSL5 and t...

hrp0084lbp-1267 | Late Breaking Posters | ESPE2015

Safety and Efficacy of Long-Acting GH (VRS-317) in Children with GHD: Effects of Dose Change in the Second Treatment Year

Bright George , Moore Wayne V , Nguyen Huong Jil , Kletter Gad B , Miller Bradley S , Fechner Patricia Y , Ng David , Humphriss Eric , Cleland Jeffrey L

Background: VRS-317, a novel fusion protein of rhGH exhibiting delayed clearance, serum half-life generally >100 h, and potential for once monthly dosing, was previously evaluated in a 6-month phase 1b/2a study of weekly, twice monthly or monthly dosing (5.0 mg/kg per month) in prepubertal GHD children (n=64).Objective and hypotheses: We evaluated whether increased VRS-317 dose from 12 to 18 months can offset the decrease in height velocitie...

hrp0092lb-20 | Late Breaking Posters | ESPE2019

Introduction of Flash Glucose Monitoring in Children with Type 1 Diabetes: Experience of a Single-Centre in Spain

Leiva-Gea Isabel , Garcia Vázquez Javier , Rocío Liñán Jurado Francisca , Angel Maese Ruiz Miguel , Jiménez Hinojosa Jose , Pedro López-Siguero Juan

Flash glucose monitoring is now included in the Portfolio of Services of the Public Health System of Andalusia in Spain. We enrolled 145 paediatric T1D diabetes patients into a prospective, interventional study of the impact of the FreeStyle Libre system on HbA1c levels in this population, as well as additional measures of glycemic health, such as Time in Range (TIR) and Time Below Range (TBR). Subjects were trained in use of the FreeStyle Libre system at the start of the stud...

hrp0092p3-119 | Fat, Metabolism and Obesity | ESPE2019

ESPE 2019. Physical Activity, Food and Metabolic Risk in Children and Adolescents

de Lamas Carmela , Vázquez Rocío , José Bedoya Juan , Aguilera Concepción , Gil-Campos Mercedes , Bueno Gloria , Moreno Luis , Gil Ángel , Leis Rosaura

Introduction:The incidence of obesity increases unstoppably in all populations and at all ages, and with it, the associated metabolic morbidity and mortality. The promotion of physical activity and a healthy diet are the fundamental elements to alleviate this situation. The objective of this study is to determine the relationship of physical activity and eating patterns with body composition, the degree of adiposity and certain metabolic risk factors.<p cl...

hrp0089p2-p071 | Diabetes &amp; Insulin P2 | ESPE2018

Clinical Details, Molecular Genetic Analysisand Clinical Pheonotype Correlation of 14 Patients with Neonatal Diabetes from The South India – A Single Centre Experience

Nagesh V Sri , Hattersley Andrew , Ellard Sian , Sethi Bipin , Franco Elisa De , Flanagan Sarah , Houghton Jayne , Venkateshwarlu M , Parekh Harsh , Dukle Vaibhav , Kelwade Jayant , Naseem Altaf , Kanithi Ravishankar , Nalli Ravi Kumar

Background: Neonatal diabetes mellitus (NDM) is a relatively rare form of monogenic diabetes and usually presents in the first 6–9 months of life. In this study, our objective was to report the clinical details, perform a detailed genetic analysis and acquire a clinical–phenotype correlation of our cohort.Materials and methods: NDM patients referred to SN Endocrine centre between period of Nov 2014 to April 2017 and patients under follow-up wit...

hrp0094fc6.2 | Bone and Mineral Metabolism | ESPE2021

Long-term effectiveness of PTH(1-34) infusion therapy for autosomal dominant hypocalcaemia type 1.

Sastre Ana , Valentino Kevin , Hannan Fadil M , Lines Kate E , Gluck Anna K , Stevenson Mark , Ryalls Michael , Gorrigan Rebecca , Pullen Debbie , Buck Jackie , Sankar Sailesh , Allgrove Jeremy , Thakker Rajesh V , Gevers Evelien F ,

Background: Patients with autosomal dominant hypocalcemia type 1 (ADH1), due to germline gain-of-function calcium-sensing receptor (CASR) mutations, have hypocalcemia and seizures, hyperphosphatemia, hypercalciuria and inappropriately low parathyroid hormone (PTH) concentrations. Treatment for ADH1 comprises calcium and vitamin D analogs, however, their use predisposes to nephrocalcinosis and renal impairment. In contrast, recombinant human PTH(1-34) may incre...